Home Featured Page 226

Featured

Latest

Is It Worth It? What Colorado’s Early Experience With Regulated Psychedelic Care Has the Field Asking, and What To Do About It

Compass Says NDA Will Be Filed Within Two Weeks, Declines to Comment on Usona

Podcast: Usona Files Psilocybin Application, We Review 610 Comments Submitted to FDA, and FDA Approves NRx’s Generic Ketamine

Usona Files Psilocybin for Depression NDA as Race With Compass Tightens

Jackie Tileston: Nondual Mysticism, 5-MeO-DMT, and the Trouble with Psychedelic Art

atai Life Sciences launches TryptageniX to further expand atai’s robust intellectual...

Editor’s Choice Award 2021-Best Study on Psychedelics and Pharmacology

MindMed Engages in Productive Pre-Submission Meeting with FDA for Development of...

Cybin Confirms Scientific Advice Meeting with UK Medical and Healthcare Products...

Delix Therapeutics Partners with the National Institute on Drug Abuse (NIDA)...

Psilera Confirms PSIL-002, A New DMT Derivative, is Well-Tolerated and Non-Hallucinogenic...

Editor’s Choice Award 2021-Best Study on Psychedelics and Nature

PT276 – Micah Haskell-Hoehl – Healing, Equity, and Federal Policy

Psychedelic Bulletin: MAPS’ $70m Investment Vehicle; atai’s Increased Stake in COMPASS;...

Psychiatrist and Addiction Researcher, Dr. Henry Kranzler Joins Entheon Advisory Board

EDITOR PICKS

Is It Worth It? What Colorado’s Early Experience With Regulated Psychedelic...

Compass Says NDA Will Be Filed Within Two Weeks, Declines to...

Podcast: Usona Files Psilocybin Application, We Review 610 Comments Submitted to...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.